Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S183000, C514S247000, C514S248000, C514S277000, C514S279000, C514S280000
Reexamination Certificate
active
07125873
ABSTRACT:
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
REFERENCES:
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6166063 (2000-12-01), Villhauer
patent: 6303661 (2001-10-01), Demuth et al.
patent: WO 97/30053 (1997-08-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 02/02560 (2002-01-01), None
Herman et al. Clinical Pharmacology & Therapeutics 2005; 78(6):675-88 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies.
“Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus”, Exp. Opin, Ther. Patents, 10(12), pp. 1937-1942 (2000).
Ashworth, et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorg. Med. Chem. Lett., vol. 6, No. 10, pp. 1163-1166, (1996).
Ashworth, et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorg. Med. Chem. Lett., vol. 6, No. 22, pp. 2745-2748, (1996).
Deacon, et al., “Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”, Biochem. Biophys. Res. Commun. vol. 294, pp. 1-4 (2002).
Stoeckel-Maschek A., et al: “Potent Inhibitors of Dipeptidyl Peptidase IV and Their Mechanisms of Inhibition” Advances in Experimental Medicine and Biology, vol. 477, pp. 117-123, (2000).
Edmondson Scott D
Fisher Michael H.
Kim Dooseop
Maccoss Malcolm
Parmee Emma R.
Durette Philippe L.
Graffeo Michel
Low Christopher S. F.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3717811